3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
Gastrointestinal
4
Thoracic
3
Dermatologic
3
Head & Neck
2
Genitourinary
2
CNS
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Endocrine
1
Breast
1
Conditions
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
pembrolizumab
2
fludarabine
2
aldesleukin
2
Nivolumab
2
Ifosfamide
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Doxorubicin
2
Cyclophosphamide
2
trametinib
1
tivozanib
1
milademetan
1
entrectinib
1
dabrafenib
1
cobimetinib
1
berzosertib
1
avelumab
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Topotecan
1
Taxes
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Microscopy, Electron
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
cobimetinib
×
Endocrine
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled